000296138 001__ 296138
000296138 005__ 20250508150918.0
000296138 0247_ $$2doi$$a10.1093/jnci/djae349
000296138 0247_ $$2pmid$$apmid:39761002
000296138 0247_ $$2ISSN$$a0027-8874
000296138 0247_ $$2ISSN$$a1460-2105
000296138 0247_ $$2ISSN$$a1475-4029
000296138 0247_ $$2altmetric$$aaltmetric:172767327
000296138 037__ $$aDKFZ-2025-00068
000296138 041__ $$aEnglish
000296138 082__ $$a610
000296138 1001_ $$aMcwilliam, Alan$$b0
000296138 245__ $$aAssociation of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
000296138 260__ $$aOxford$$bOxford Univ. Press$$c2025
000296138 3367_ $$2DRIVER$$aarticle
000296138 3367_ $$2DataCite$$aOutput Types/Journal article
000296138 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1746709720_30
000296138 3367_ $$2BibTeX$$aARTICLE
000296138 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296138 3367_ $$00$$2EndNote$$aJournal Article
000296138 500__ $$aVolume 117, Issue 5, May 2025, Pages 1018–1026
000296138 520__ $$aOverlapping genes are involved with rheumatoid arthritis (RA) and DNA repair pathways. Therefore, we hypothesised that patients with a high polygenic risk score (PRS) for RA will have an increased risk of radiotherapy (RT) toxicity given the involvement of DNA repair.Primary analysis was performed on 1494 prostate cancer, 483 lung cancer and 1820 breast cancer patients assessed for development of RT toxicity in the REQUITE study. Validation cohorts were available from the Radiogenomics Consortium. All patients had undergone curative-intent radiotherapy and were assessed prospectively for toxicity. Germline genomic data was available for all patients, allowing a PRS to be calculated using 101 RA risk variants. PRS was analysed as a continuous variable and with >90th percentile cut-off. Associations with acute and late standardised total average toxicity (STAT) scores and individual toxicity end-points were analysed in multivariable models with preselected adjustment variables.Increasing PRS for RA did not increase the risk of acute or late STAT in any cohort. There was an increased risk of late oesophagitis in the lung cancer cohort (coefficient 0.018, p = .01), however this was not validated (p = .79). No individual acute or late toxicity endpoints were significantly associated with PRS for the prostate or breast cohorts. No significant results were found in the validation cohorts in multivariable models.Patients with a high genetic risk for RA do not show increased levels of toxicity after radiotherapy suggesting treatment planning does not need to be modified for such patients.
000296138 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000296138 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296138 650_7 $$2Other$$aPolygenetic risk scores
000296138 650_7 $$2Other$$aRadiotherapy toxicity
000296138 650_7 $$2Other$$aRheumatoid arthritis
000296138 7001_ $$aMarshall, Deborah$$b1
000296138 7001_ $$aKerns, Sarah L$$b2
000296138 7001_ $$aBarnett, Gillian C$$b3
000296138 7001_ $$aVega, Ana$$b4
000296138 7001_ $$aKapouranis, Thodori$$b5
000296138 7001_ $$aAguado Barrera, Miguel E$$b6
000296138 7001_ $$aAvuzzi, Barbara$$b7
000296138 7001_ $$aAzria, David$$b8
000296138 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b9
000296138 7001_ $$aChoudhury, Ananya$$b10
000296138 7001_ $$aCoedo Costa, Carla$$b11
000296138 7001_ $$aDunning, Alison$$b12
000296138 7001_ $$aFarcy-Jacquet, Marie-Pierre$$b13
000296138 7001_ $$aFaivre-Finn, Corinne$$b14
000296138 7001_ $$aGutiérrez-Enríquez, Sara$$b15
000296138 7001_ $$aFuentes Río, Olivia$$b16
000296138 7001_ $$aGómez Caamaño, Antonio$$b17
000296138 7001_ $$aLambrecht, Maarten$$b18
000296138 7001_ $$aLópez Pleguezuelos, Carlos$$b19
000296138 7001_ $$aRancati, Tiziana$$b20
000296138 7001_ $$aRattay, Tim$$b21
000296138 7001_ $$aDe Ruysscher, Dirk$$b22
000296138 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b23$$udkfz
000296138 7001_ $$aSperk, Elena$$b24
000296138 7001_ $$aTalbot, Christopher$$b25
000296138 7001_ $$aWebb, Adam$$b26
000296138 7001_ $$aVeldeman, Liv$$b27
000296138 7001_ $$aRosenstein, Barry S$$b28
000296138 7001_ $$aWest, Catharine M L$$b29
000296138 7001_ $$aConsortium, REQUITE$$b30$$eCollaboration Author
000296138 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djae349$$gp. djae349$$n5$$p1018–1026$$tJournal of the National Cancer Institute$$v117$$x0027-8874$$y2025
000296138 909CO $$ooai:inrepo02.dkfz.de:296138$$pVDB
000296138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000296138 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000296138 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000296138 9141_ $$y2025
000296138 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000296138 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2022$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000296138 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2022$$d2023-10-21
000296138 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000296138 980__ $$ajournal
000296138 980__ $$aVDB
000296138 980__ $$aI:(DE-He78)C020-20160331
000296138 980__ $$aUNRESTRICTED